Delving into the Latest Updates on Silibinin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Silibinin (INN), Silibinin A, Silybin A

+ [12]

Target

HSP90

Action

inhibitors

Mechanism

HSP90 inhibitors(Heat shock 90kDa proteins inhibitors)

Therapeutic Areas

Digestive System DisordersCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

Liver DiseasesDiabetic RetinopathyCushing Syndrome

Inactive Indication

Beta-ThalassemiaIron Overloadliver function failure+ [1]

Originator Organization-

Active Organization

Augusta UniversityMax-Planck Institute of Psychiatry

Inactive Organization

Nhat Nhat Pharmaceutical Co.，LtdMadaus SA

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC25H22O10

InChIKeySEBFKMXJBCUCAI-HKTJVKLFSA-N

CAS Registry22888-70-6

The goal of this clinical trial is to evaluate the possible beneficial effect of silymarin in Ulcerative Colitis adult patients receiving mesalamine. This is trial that will be conducted on 44 adult patients with Ulcerative Colitis. Patients will be enrolled after obtaining an informed consent from them or their guardians.
Patients will be recruited from Rajhy Hospital Outpatient Clinics and Health Insurance Outpatient Clinics at Mabarra Hospital in Assiut, Egypt. The patients will be randomized based on hospital admission days into two groups:
* Group Ⅰ (Control group): 22 patients will receive Mesalamine (2g/day) + Azathioprine (50mg/day) for 3 months.
* Group Ⅱ (Silymarin group): 22 patients will receive Mesalamine (2g/day) + Azathioprine (50mg/day) + Silymarin (140 mg/day) for 3 months.
The primary outcome will be clinical improvement defined as a 2 point or more decrease in the Mayo score from baseline. The secondary outcomes will be the change in the level of fecal calprotectin, superoxide dismutase and TNF-α.

Start Date01 Feb 2025

Sponsor / Collaborator

Tanta University

IRCT20200825048515N77

/ RecruitingPhase 3IIT

Protective effect of Silymarin on liver during coronary artery bypass surgery

Start Date04 Jan 2025

Sponsor / Collaborator

Isfahan University of Medical Sciences

IRCT20200408046990N17

/ RecruitingPhase 3IIT

Investigation of the Effect of nano-silymarin on preventing Anthracycline-Induced cardiotoxicity in patients with breast cancer

Start Date21 Dec 2024

Sponsor / Collaborator

Mashhad University of Medical Sciences

100 Clinical Results associated with Silibinin

Login to view more data

100 Translational Medicine associated with Silibinin

Login to view more data

100 Patents (Medical) associated with Silibinin

Login to view more data

6,691

Literatures (Medical) associated with Silibinin

01 Dec 2025·Molecular Biology Reports

The synergistic effects of citicoline and silymarin on liver injury and thyroid hormone disturbances in γ-irradiated rats

Article

Author: Abdel-Aziz, Nahed ; Ibrahim, Ehab A ; El-Bahkery, Azza

BACKGROUNDExposure to ionizing radiation is inevitable due to its extensive use in industrial and medical applications. The search for effective and safe natural therapeutic agents as alternatives to chemical drugs is crucial to mitigate their side effects. This study aimed to evaluate the effects of citicoline as a standalone treatment or in combination with the anti-hepatotoxic drug silymarin in protecting against liver injury caused by γ-radiation in rats.METHODS AND RESULTSThe rats were exposed to γ-radiation (7 Gy) and treated with citicoline (300 mg/kg/day) and/or silymarin (50 mg/kg/day). The results showed that citicoline alleviated liver damage in irradiated rats by reducing hepatic malondialdehyde levels, serum aspartate aminotransferase activity, and inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and nuclear factor-kappa B (NF-κB). It also increased acetylcholine (ACh) levels and the gene expression of the anti-inflammatory protein α7 nicotinic acetylcholine receptor (α7nAChR). Additionally, citicoline improved serum triiodothyronine (T3) levels, thyroid hormone receptor beta (TRβ) gene expression, and iodothyronine deiodinase type 1 activity in hepatic tissues of irradiated rats. Furthermore, citicoline enhanced the effects of silymarin on thyroxine (T4), TRβ, ACh, and α7nAChR when co-administered in irradiated rats. Histopathological analysis confirmed these findings, demonstrating improved liver tissue structure.CONCLUSIONSCiticoline mitigates γ-radiation-induced liver damage by reducing oxidative stress, activating the cholinergic anti-inflammatory pathway, and modulating thyroid hormone metabolism. These findings support the use of citicoline as a safe standalone treatment or as an adjuvant with silymarin for managing liver damage and thyroid hormone disturbances caused by γ-irradiation.

01 Jun 2025·Toxicology Reports

The hepatoprotective effects of the polyphenol-enriched n-butanol fraction of Cnicus benedictus against carbon tetrachloride-induced liver fibrosis in rats: In vivo study

Article

Author: Mohammed, Mohammed Jasim ; Kadhim, Haitham Mahmood

Liver fibrosis is a continuous wound-healing response to chronic injury caused by various chemical, virus, and pathological disorders; the lack of approved drugs or methods to reverse or prevent liver fibrosis makes it an interesting area of research. This study investigates the potential hepatoprotective effects of the phenolic extract of Cnicus benedictus in rat's module of liver fibrosis. Liver fibrosis was induced by intraperitoneal injection of carbon tetrachloride (CCl₄) for six consecutive weeks; the butanol fraction of Cnicus and silymarin was administered orally concurrently with CCl₄. After six weeks, all animals were euthanized. Rat liver tissue levels of malondialdehyde (MDA) and glutathione (GSH) were measured, and serum liver enzymes and protein were measured using the ELISA technique. Histopathological study and immunohistochemistry of liver tissue for transforming growth factor (TGF-β1), alpha-smooth muscle actin (α-SMA), and hydroxyproline were assessed. In HPLC analysis, Cnicus extract showed several components, including quercetin, gallic acid, rutin, kaempferol, silibinin, and apigenin. Treatment with Cnicus butanol extract reduces serum ALT, AST, bilirubin, and albumin levels compared to induction. Additionally, Cnicus extract increases liver GSH levels and decreases liver MDA levels compared to induction. Liver tissue of TGF-β1, α-SMA, and hydroxyproline expression was downregulated in rats receiving Cnicus extract. Liver tissue histopathology showed improvement in its features compared to the induction group. In conclusion, oral administration of the polyphenol-enriched n-butanol fraction of Cnicus benedictus showed a protective effect on liver fibrosis caused by CCl4, possibly through antioxidant and anti-inflammatory mechanisms.

01 May 2025·Biosensors and Bioelectronics

A robust H2O2-responsive AIEgen with multiple-task performance: Achieving food analysis, visualization of dual organelles and diagnosis of liver injury

Article

Author: Zhang, Ao ; Zhao, Xuan ; Liu, Nianjia ; Cao, Zhixing ; Li, Yuzhi ; Zhou, Houcheng ; Deng, Yun ; Li, Longxuan ; Li, Jia ; Fang, Yuyu ; Kang, Xin ; Peng, Cheng

Drug- and alcohol-induced liver injury poses a serious threat to human health with long-lasting clinical, social and economic consequences. As a reactive oxygen species (ROS), hydrogen peroxide (H₂O₂) is widely-used as a molecular biomarker of liver injury. H₂O₂ is also utilized as a processing aid in the food industry. Therefore, monitoring the levels of H₂O₂ in liver and food samples is important for disease diagnosis and food safety demanding the development of efficient sensing and visualization tools. To address this challenge, we report a novel aggregation-induced emission (AIE) fluorescent probe for detecting H₂O₂ named TVQ-B, featuring near-infrared (NIR) emission (740 nm), large Stokes shift (195 nm), fast response time and high selectivity. Interestingly, H₂O₂ can activate the dual organelles targeting ability of TVQ-B for mitochondria and lipid droplets, enabling dual-channel imaging of H₂O₂. Importantly, the TVQ-B probe has been successfully used to monitor H₂O₂ in food samples, living cells, zebrafish and mice. This fluorescence imaging approach using endogenous H₂O₂ as a marker provides a robust and convenient diagnostic protocol for drug- and alcohol-induced liver injury. Based on this protocol, TVQ-B-based visualization provided potent evidence for the therapeutic efficacy of natural flavonolignan silybin for the reduction of negative effects of alcohol consumption.

1

News (Medical) associated with Silibinin

16 Feb 2024

·www.prnewswire.com

Capsulyte Unveils PREGAME: The Ultimate Solution for Party Recovery, Marking Its Debut at DC Fashion Week

Capsulyte PREGAME, a doctor formulated supplement to aid alcohol recovery, launches at DC Fashion Week as the hangover recovery market is set to grow over the next decade. CRANBURY, N.J., Feb. 16, 2024 /PRNewswire/ -- Capitalizing on cutting-edge ingredients, Capsulyte's PREGAME has emerged as the most advanced product to aid in party recovery and address symptoms often associated with hangovers. As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite. This invitation further underscores Capsulyte's commitment to excellence and positions PREGAME as the preferred choice for discerning individuals seeking to enjoy social occasions to the fullest, without the next-day regrets. Many individuals face the unpleasant reality of hangover symptoms such as headaches, fatigue, and nausea, resulting from alcohol consumption. These effects can be primarily attributed to acetaldehyde, a toxic compound that is created when the liver metabolizes alcohol. According to Persistence Market Research, the global hangover recovery market is estimated to reach $4.2 billion by the year 2030. PREGAME is uniquely situated to help solve the issue of acetaldehyde accumulation among individuals who want to live healthy, balanced lives while also maintaining their productivity. PREGAME addresses the challenge of party recovery head-on with a formulation enriched with the scientifically backed ingredients Siliphos® and Clovinol® to support liver detoxification, overall liver health, and acetaldehyde metabolism. Siliphos®, a patented botanical derivative from milk thistle, has been clinically shown to improve liver function, inhibit fibrotic cells, and shield against oxidative stress. Its unique Phytosome technology enhances the bioavailability of silybin, a key component for liver health that is otherwise poorly absorbed by the body. This innovative approach ensures marked improvement over standard milk thistle extracts, offering comprehensive liver protection and recovery. Clovinol®, sourced from the potent spice clove, is distinguished by its capacity to increase the potent antioxidant, glutathione. It's also a robust liver protector that accelerates the elimination of acetaldehyde from the body up to 2.5 times faster than usual, thereby reducing alcohol's negative effects and the severity of symptoms associated with hangovers. With the synergy of Siliphos® and Clovinol®, combined with Dihydromyricetin (DHM) and N-Acetyl Cysteine (NAC), PREGAME represents the pinnacle of a doctor-formulated, research-backed solution for those seeking to mitigate the aftereffects of alcohol consumption. As the brand marks its presence at DC Fashion Week, Capsulyte is set to redefine the standards of social indulgence and wellness. Its participation not only highlights the efficacy and luxury associated with PREGAME but also solidifies Capsulyte's stance as a trailblazer in the dietary supplement industry. Unlock the ability to embrace a healthier, more vibrant lifestyle with Capsulyte's PREGAME, where premium care meets unparalleled social experiences. Capsulyte's PREGAME and HYDRATION are available on the store site and Amazon. FDA Disclaimer: The statements made regarding this product have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from healthcare practitioners. Please consult your doctor. The news site hosting this press release is not associated with Capsulyte. It is merely publishing a press release announcement submitted by a company, without any stated or implied endorsement of the product or service. About Capsulyte Capsulyte is a doctor-founded dietary supplement company dedicated to enhancing the health and wellbeing of individuals through scientifically backed, innovative products. Specializing in alcohol and party recovery solutions, Capsulyte is committed to delivering superior quality, efficacy, and safety in every product, supporting people in living their best lives. For more information, visit Press Contact Dan Nguyen 908-292-3110 SOURCE Capsulyte

100 Deals associated with Silibinin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08515	Silibinin	A05BA03	DB09298

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Liver Diseases	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
liver function failure	Phase 2	Vietnam	Nhat Nhat Pharmaceutical Co.，Ltd	15 Jun 2017
Beta-Thalassemia	Phase 2	Iran	Madaus SA	01 Mar 2009
Iron Overload	Phase 2	Iran	Madaus SA	01 Mar 2009
Nonalcoholic Steatohepatitis	Phase 2	United States	Madaus SA	01 Apr 2008
Diabetic Retinopathy	Preclinical	United States	Augusta University	01 May 2022
Cushing Syndrome	Preclinical	Germany	Max-Planck Institute of Psychiatry	09 Feb 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SUSTAIN (ASCO2023) Manual	Phase 2	Brain metastases	30	silibinin	(qizotveqmt) = Two pts discontinued silibinin-based nutraceutical assumption due to G1 nausea. No other adverse events were reported. qxinulwmne (hempqpwzcp )	Positive	31 May 2023
NCT00915681 (CTgov)	Phase 2	liver function failure \| Mushroom Poisoning	148	Silibinin	getvsjewvt(ghwjxspcvs) = aoclkxtrxh qgswxgpfxt (bbpseohawl, sehtxvbddu - imlqwjhsem) View more	-	07 Apr 2022
UEGW2019	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	80	Vitamin E 400 IU	dcavumdkrx(vwnqxesqfx) = zgnjawkawb etwujyjukf (irnyknbswi ) View more	Positive	01 Oct 2019
				Silymarin 280mg	dcavumdkrx(vwnqxesqfx) = zixklvjguj etwujyjukf (irnyknbswi ) View more
NCT00680407 (Pubmed)	Phase 2	Nonalcoholic Steatohepatitis	78	Legalon® 420 mg	mqbourjmky(vsrguzpysf) = aoghxdcmry gztygxsldq (lonwhunrwz )	-	01 Jan 2019
				Legalon® 700 mg	mqbourjmky(vsrguzpysf) = jocckomtbr gztygxsldq (lonwhunrwz )
NCT02006498 (Pubmed \| Clin Gastroenterol Hepatol) Manual	Phase 2	Nonalcoholic Steatohepatitis	99	Silymarin	(pxsqtjzatq) = jenuiurapj imcvsrlwej (svjpoltgvk ) View more	Positive	01 Dec 2017
				Placebo	(pxsqtjzatq) = jyiofjqfzu imcvsrlwej (svjpoltgvk ) View more
NCT00680407 (SyNCH, CTgov)	Phase 2	Nonalcoholic Steatohepatitis	78	Silymarin 420 mg (Silymarin 420 mg)	(uhpuewpwhx) = okbllbncre gmtimgfiog (bxuzyqhvbu, xenxkucbut - pooqhzjogt) View more	-	29 Jan 2016
				Silymarin 700 mg (Silymarin 700 mg)	(uhpuewpwhx) = crkemkwlvo gmtimgfiog (bxuzyqhvbu, wlyqczjmwb - axdcxlzlxn) View more
Pubmed \| Chin J Integr Med	Not Applicable	Colitis, Ulcerative	80	Silymarin	(psfsgbxwpw) = gzlqsoeoht tvayyqajta (vmcollgwvr ) View more	Positive	01 Dec 2015
				Placebo	(psfsgbxwpw) = shfhpkcdpu tvayyqajta (vmcollgwvr ) View more
Pubmed	Not Applicable	Metabolic dysfunction-associated steatotic liver disease	36	Silymarin plus vitamin E	ctapkuviiu(gautbeymho) = rximytbkdw vmjgoijycp (qsejscsbbx )	Positive	01 Aug 2015
				silymarin (Hypocaloric diet)	ctapkuviiu(gautbeymho) = xvwnhqebib vmjgoijycp (qsejscsbbx )
NCT00487721 (CTgov)	Phase 2	Localized Prostate Carcinoma	12	Silibin-Phytosome (Silibin-Phytosome)	rsqdqgqegt(lrmyrgjwes) = mfqxiflbgf rciygowopz (auopindhtx, fdxmapdodl - oxoutcuvre) View more	-	28 Feb 2014
				placebo (Control)	bebtgvafbu(mexxdbamdw) = ymlpdfgqck tuhtggbufi (ctzsztaumx, pifdvdyzxk - gavodcuyab) View more
AACR2013	Not Applicable	Basal Cell Carcinoma	-	Silibinin	olgwvyfwgw(mzpcawbklw) = fteucudyky aoejovybpi (rqlgxtpyxo ) View more	-	15 Apr 2013
				DMSO	olgwvyfwgw(mzpcawbklw) = qzpskeozhd aoejovybpi (rqlgxtpyxo ) View more